Premium
Emergence of cutaneous neosporosis in a dog receiving immunosuppressive therapy: molecular identification and management
Author(s) -
Legnani Sara,
Pantchev Nikola,
Forlani Annalisa,
Zini Eric,
Schares Gereon,
Balzer Jörg,
Roccabianca Paola,
Ferri Filippo,
Zanna Giordana
Publication year - 2016
Publication title -
veterinary dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 60
eISSN - 1365-3164
pISSN - 0959-4493
DOI - 10.1111/vde.12273
Subject(s) - neospora caninum , medicine , immunosuppression , disease , parasitic disease , serology , neospora , immunohistochemistry , coccidiosis , immune system , clindamycin , immunology , pathology , antibody , biology , toxoplasma gondii , microbiology and biotechnology , antibiotics
Background Neosporosis is a multisystemic disease caused by the intracellular protozoan Neospora caninum . In dogs the disease primarily affects the central nervous system. Canine cutaneous neosporosis is a rare condition often associated with old age or concurrent immunosuppressive treatments for different underlying conditions. Animals A 10‐year‐old female spayed golden retriever dog affected by primary immune‐mediated myelofibrosis and treated with immunosuppressive therapies for 6 weeks that developed severe cutaneous lesions. Methods Definitive diagnosis was based on several investigation techniques including serology (immunoblotting), immunohistochemistry (IHC), species‐specific conventional and real‐time PCR , and DNA sequencing. Results Remission of cutaneous neosporosis was obtained with the administration of clindamycin while the concurrent immunosuppressive therapy was maintained to manage the underlying primary condition. Conclusions and clinical importance To the best of the authors' knowledge this is the first report of species‐specific PCR and DNA sequencing used as diagnostic methods for canine cutaneous neosporosis emerging in a dog receiving immunosuppressive therapy.